MiR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKC&#1013; and ZEB1 inhibition by R. El Bezawy et al.
RESEARCH Open Access
miR-205 enhances radiation sensitivity of
prostate cancer cells by impairing DNA
damage repair through PKCε and ZEB1
inhibition
Rihan El Bezawy1, Stella Tinelli1, Monica Tortoreto1, Valentina Doldi1, Valentina Zuco1, Marco Folini1,
Claudio Stucchi2, Tiziana Rancati3, Riccardo Valdagni3,4, Paolo Gandellini1 and Nadia Zaffaroni1*
Abstract
Background: Radiotherapy is one of the main treatment options for non-metastatic prostate cancer (PCa).
Although treatment technical optimization has greatly improved local tumor control, a considerable fraction
of patients still experience relapse due to the development of resistance. Radioresistance is a complex and
still poorly understood phenomenon involving the deregulation of a variety of signaling pathways as a
consequence of several genetic and epigenetic abnormalities. In this context, cumulative evidence supports a
functional role of microRNAs in affecting radioresistance, suggesting the modulation of their expression as a
novel radiosensitizing approach. Here, we investigated for the first time the ability of miR-205 to enhance the
radiation response of PCa models.
Methods: miR-205 reconstitution by a miRNA mimic in PCa cell lines (DU145 and PC-3) was used to elucidate miR-
205 biological role. Radiation response in miRNA-reconstituted and control cells was assessed by clonogenic assay,
immunofluorescence-based detection of nuclear γ-H2AX foci and comet assay. RNAi was used to silence the miRNA
targets PKCε or ZEB1. In addition, target-protection experiments were carried out using a custom oligonucleotide
designed to physically disrupt the pairing between the miR-205 and PKCε. For in vivo experiments, xenografts generated
in SCID mice by implanting DU145 cells stably expressing miR-205 were exposed to 5-Gy single dose irradiation using an
image-guided animal micro-irradiator.
Results: miR-205 reconstitution was able to significantly enhance the radiation response of prostate cancer cell lines and
xenografts through the impairment of radiation-induced DNA damage repair, as a consequence of PKCε and ZEB1
inhibition. Indeed, phenocopy experiments based on knock-down of either PKCε or ZEB1 reproduced miR-205
radiosensitizing effect, hence confirming a functional role of both targets in the process. At the molecular level, miR-205-
induced suppression of PKCε counteracted radioresistance through the impairment of EGFR nuclear translocation and the
consequent DNA-PK activation. Consistently, disruption of miR-205-PKCε 3’UTR pairing almost completely abrogated the
radiosensitizing effect.
Conclusions: Our results uncovered the molecular and cellular mechanisms underlying the radiosensitizing effect
of miR-205. These findings support the clinical interest in developing a novel therapeutic approach based on
miR-205 reconstitution to increase PCa response to radiotherapy.
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Background
Radiotherapy is one of the main treatment options for
non-metastatic prostate cancer (PCa) [1]. Although treat-
ment technical optimization has greatly improved local
tumor control, a considerable fraction of patients still ex-
perience relapse due to development of resistance [2].
Radioresistance is a complex and still poorly understood
phenomenon involving the deregulation of a variety of sig-
naling pathways as a consequence of several genetic and
epigenetic abnormalities [3]. In this context, mounting
evidence supports the ability of microRNAs (miRNAs) to
interfere with different radioresistance-associated path-
ways, such as DNA-repair [4], epithelial-to-mesenchymal
transition [5–8], and stemness [9]. miRNAs are endogen-
ous small non-coding RNA molecules that negatively
regulate gene expression [10]. The notion that miRNAs
are heavily deregulated in PCa, together with the ability of
a single miRNA to act as negative regulator of several
genes and consequently modulate multiple cellular pro-
cesses, has lead to increasing interest in defining a func-
tional association between miRNA expression and
radiation response [11].
Thus far, most studies assessing the involvement of
specific miRNAs in radiosensitivity/radioresistance pro-
file of PCa were limited to in vitro cell lines and gener-
ated controversial results [11]. A few in vivo studies on
human PCa xenografts identified miRNAs promoting
radioresistance, such as miR-620, which regulates prosta-
glandin E2 levels through direct targeting of hydroxy-
prostaglandin dehydrogenase 15 [12], and miR-95, which
targets the sphingolipid phosphatase SGPP1 [13]. In the
other hand, miR-145 and miR-890 were shown to in-
crease radiation sensitivity of human PCa xenografts
through down-regulation of multiple DNA repair genes
[14, 15]. More recently, we demonstrated that
miR-875-5p significantly enhances the radiation response
of both in vitro and in vivo PCa experimental models by
concomitantly counteracting epithelial-to-mesenchymal
transition (EMT) and impairing DNA damage repair
through the suppression of the EGFR-ZEB1 axis [16].
Here, we investigated the ability of miR-205 to radio-
sensitize human PCa preclinical models. A lower
miR-205 expression was consistently found in PCa com-
pared with matched normal prostate tissues in different
studies [17–19]. In addition, we previously demonstrated
that miR-205 is essential for maintenance of the basal
membrane in prostate epithelium [20], and that it blocks
tumor-driven activation of surrounding fibroblasts by re-
ducing secretion of the pro-inflammatory cytokine IL-6
[21], overall supporting a miRNA oncosuppressive func-
tion in PCa. The possible relevance of miR-205 for PCa
radiation response is based on our previous observation
that its reconstitution in PCa cells counteracts EMT [17]
and increases the antitumor activity of the DNA
damaging agent cisplatin in vitro and in vivo, as a conse-
quence of autophagy impairment [22], as well as on the
reported evidence that PKCε, a direct miR-205 target
[17], plays a role in the nuclear translocation of EGFR,
which is lost upon PKCε knockdown thus impairing
DNA-double strand break (DSB) repair [23]. Consist-
ently, results from this study indicate that miR-205 re-
constitution increases the radiation response of human
PCa in vitro and in vivo models through the repression
of the PKCε-EGFR-DNA-PK axis.
Materials and methods
Experimental models
The human DU145 and PC-3 PCa cell lines were pur-
chased from the American Type Culture Collection
(ATCC, Manassas, VA, USA) and maintained in
RPMI-1640 medium supplemented with 10% fetal bo-
vine serum (FBS). Cell lines were authenticated and peri-
odically monitored by genetic profiling using short
tandem repeat analysis (AmpFISTR Identifiler PCR amp-
lification kit, Thermo Fisher Scientific Inc., Waltham,
MA, USA).
Cell transfection
Cells seeded at the appropriate density were transfected
for 4 h with 20 nM mirVana miRNA mimic and negative
control molecules (Thermo Fisher Scientific Inc) or with
20 nM siRNA molecules using Lipofectamine 2000
(Thermo Fisher Scientific Inc), according to the manu-
facturer’s instructions. In miR-Mask experiments, 20 nM
PKCε-miScript Target Protector (Qiagen, Hilden,
Germany) was transfected alone or in combination with
miR-205 mimic. SiRNAs targeting PKCε, ZEB1, LAMP3
and RAB27A were designed using siMAX Design Soft-
ware and synthesized by Eurofin MWG Operon (Ebers-
berg, Germany). A control siRNA with no homology to
any known human mRNA was also used. Hereafter,
miR-205 synthetic mimic will be referred to as miR-205,
negative mock control oligomer as Neg, PKCε-miScript
Target Protector as miR-Mask, PKCε siRNA as siPKCε,
ZEB1 siRNA as siZEB1, LAMP3 siRNA as siLAMP3,
RAB27A siRNA as siRAB27A and control siRNA as
siCTRL. DU145 clones stably expressing miR-205 were
previously established as described in [22] and will be re-
ferred to as Vec miR-205 and cell stably transfected with
negative control as Vec Neg.
Clonogenic assay
Transfected cells were exposed to increasing doses (2–8
Gy) of irradiation delivered as a single dose using the
137Cs γ-irradiator IBL-437 (dose rate 5.2 Gy/min). Cells
were then seeded at increasing density (500–8000 cells/
well), in triplicate, in 6-well plates in RPMI medium
containing 10% FBS. After 10 and 14 days, DU145 and
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PC-3 colonies, respectively, were fixed with 70% ethanol,
stained with crystal violet in 70% ethanol, and counted.
The plating efficiency was calculated as the ratio of the
number of colonies (consisting of at least 50 cells) to the
number of seeded cells. The surviving fraction was cal-
culated as the ratio of the plating efficiency of the irradi-
ated cells to that of the non-irradiated ones. Triplicate
wells were set up for each condition.
In vivo experiments
All animal experiments were approved by the Ethics
Committee for Animal Experimentation of Fondazione
IRCCS Istituto Nazionale dei Tumori. Ten million
DU145 cells (Vec Neg and Vec miR-205 clones) were
injected into the right flank of eight-week-old male SCID
mice, and when tumors reached ~ 100mm3 (Width2 x
Length/2), mice were randomly assigned to control or
radiation treatment groups (n = 8). Mice received 5 Gy
single dose irradiation using a micro-CT/microirradiator
(225Cx, Precision X-ray).
miRNA and gene expression analysis
Quantification of miR-205 and mRNA expression levels
was assessed by qRT-PCR using the following TaqMan
microRNA or gene expression assays (Thermo Fisher
Scientific Inc): miR-205,000,509; PKCε Hs00942886_m1
and ZEB1 Hs00232783_m1. Amplifications were run on
the 7900HT Fast Real-Time PCR System. Data were ana-
lyzed by SDS 2.2.2 software (Thermo Fisher Scientific
Inc) and reported as relative quantity with respect to a
calibrator sample using the 2-ΔΔCt method. RNU48
(PN4427975) and GAPDH (PN4326317E) were used as
endogenous controls.
Immunoblotting analyses
For immunoblotting, 20 μg of cell lysates was fractioned
by SDS-PAGE and transferred onto nitrocellulose mem-
branes using standard protocols. Equal protein loading
was verified by Ponceau staining. Filters were blocked in
PBS-Tween-20/0.5% skim milk and probed overnight
with specific antibodies for PKCε (ab63638 and
ab124806, Abcam, Cambridge, United Kingdom), EGFR
(sc-03, Santa Cruz), pEGFR-T654 (ab78283, Abcam),
ZEB1 (sc-10,572, Santa Cruz), DNA-PK (MS 423-PO,
Thermo Fisher Scientific Inc), DNA-PK-T2609
(ab174576, Abcam). β-actin (a2066, Sigma-Aldrich, St.
Louis, MO) or Vinculin (V9131, Sigma-Aldrich) and
HDAC (877–616-cell, Cell Signaling) were used as equal
protein loading controls. For phospho-DNA-PK evalu-
ation, 48 h after transfection, cells were harvested at 30
and 60 min for subcellular protein fractionation by Sub-
cellular Protein Fractionation Kit (Thermo Fisher Scien-
tific). The filters were then incubated with the secondary
peroxidase linked whole antibodies. Bound antibody was
detected using the Novex ECL, HRP Chemiluminescent
substrate Reagent Kit (Thermo Fisher Scientific Inc). For
the preparation of figures, we cropped the original west-
ern blots to generate the figure panels with the relevant
lanes. Cropped images were then subjected to uniform
image enhancement of contrast and brightness. Molecu-
lar weights were determined using the colorimetric Pre-
cision Plus Protein Standard (Bio-Rad) and standard
protein bands were removed from the chemiluminescent
blot image.
Immunofluorescence
Cells grown on glass coverslips were fixed with 4% for-
maldehyde and permeabilized with cold methanol/acet-
one solution. Cells were probed with FITC-labeled
phalloidin (P5282; Sigma- Aldrich) or with primary anti-
body for phospho-Histone H2AX (ab11174, Abcam) and
subsequently with Alexa Fluor488-labeled or Alexa
Fluor594-labeled (Thermo Fisher Scientific Inc) second-
ary antibodies for 1 h at room temperature. Nuclei were
counterstained with DAPI (Thermo Fisher Scientific
Inc). Images were acquired by Nikon Eclipse E600
microscope using ACT-1 software (Nikon) and proc-
essed with ImageJ.
Comet assay
The alkaline Comet assay (Trevigen Inc., Bologna, Italy)
was performed on transfected cells 4 h from irradiation (4
Gy), according to the manufacturer’s instructions. Cells
were suspended in low melting agarose and layered on
microscope slides. Cells were then lysed to release the
DNA. Electrophoresis was carried out under alkaline con-
ditions. After electrophoresis for 10min at 1 V/cm, slides
were washed in water and dehydrated with ethanol,
air-dried and then DNA was stained with SYBR Green.
Comets were imaged using a fluorescence microscope
equipped with a video camera (Jai Pulnix, Sunnyvale, CA),
and quantitative assessment of DNA damage was obtained
using the Comet Assay IV software (Perceptive Instru-
ments, Suffolk, UK). Tail moments were determined by
counting at least 200 comets/condition.
Statistical analyses
Data are shown as mean values ± SD from at least three
independent experiments. Statistical analysis was per-
formed by two-tailed Student’s t test. P-values < 0.05
were considered statistically significant.
Results
miR-205 enhances PCa cell sensitivity to radiation
To assess the potential of miR-205 as a modulator of radi-
ation sensitivity of PCa cells, we adopted a
gain-of-function approach. Transfection of DU145 and
PC-3 cell lines – which inherently express almost
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undetectable levels of the miRNA [17] – with a miR-205
synthetic mimic resulted in its persistent endogenous ex-
pression, still appreciable after ten days, being the values
of relative expression highly significant, albeit reduced
over time. (Fig. 1A, left panels). Consistent with previous
data [17], restoring the expression of miR-205 did not ap-
preciably affect cell proliferative potential, as indicated by
the plating efficiencies of transfected DU145 and PC-3
cells (0.20 and 0.29, respectively), which were superimpos-
able to those of corresponding negative-control transfec-
tants (0.22 and 0.28, respectively). Interestingly, miR-205
reconstitution resulted in an increased sensitivity of both
cell lines to radiation, as suggested by the reduction in
their clonogenic cell survival compared to controls, which
was statistically significant along the whole range of doses
(Fig. 1a, right panels).
Notably, the radiosensitizing effect was maintained in a
polyclonal population of DU-145 cells stably transfected
with a vector containing the hairpin precursor sequence
of miR-205 [22], where the persistent miRNA overexpres-
sion, although to a lower extent compared to transiently
reconstituted DU145 cells (Fig. 1b, left panel), was suffi-
cient to induce a significant enhancement of radiation re-
sponse (Fig. 1b, right panel). Again, miR-205 stable
reconstitution did not affect the clonogenic potential of
DU145 cells (plating efficiencies, 0.13 and 0.15 in
miRNA-205- and negative control-transfected cells,
respectively).
These results suggest that miR-205 is endowed with a
radiosensitizing potential in PCa cell models.
miR-205 impairs cell repair of radiation-induced DNA
damage
To test whether the observed radiosensitizing effect
was based on miR-205 ability to interfere with cell
mechanisms of DNA repair, we assessed the persist-
ence of radiation-induced damage by evaluating the
kinetics of accumulation and removal of γH2AX foci,
a specific marker of the presence of DNA-DSBs [24].
Immunofluorescence staining of γH2AX showed that
the treatment induced an extensive and comparable
DNA damage in both miR-205-reconstituted and
control cells, as indicated by the presence of high
positivity (> 10 foci/cell) to γH2AX in > 90% of cells
at 1 h from radiation treatment (Fig. 2a and b). However,
γH2AX foci resolution at 4 and 8 h after irradiation was
markedly delayed in miR-205-reconstituted cells, indicat-
ing that the miRNA impairs cell proficiency in recovering
from radiation-induced DNA-DSBs (Fig. 2a and b). Con-
sistently, when assessing DNA damage at a single cell level
by comet assay, miR-205-reconstituted cells presented sig-
nificantly extended comet tail moments, as detected at 4 h
after irradiation, reflecting the presence of a markedly
higher amount of unrepaired DNA breaks with respect to
control cells (Fig. 2c).
These findings support the hypothesis that miR-205 im-
pairs the ability of PCa cells to repair radiation-induced
DNA damage.
miR-205 enhances in vivo response to radiotherapy in
PCa xenografts
Our in vitro findings were challenged in the in vivo set-
ting by subcutaneously transplanting DU145 cells stably
transfected with miR-205-expressing vector and control
vector into SCID mice to generate xenografts. The en-
hanced expression of the miRNA was confirmed by
qRT-PCR (Fig. 3a). Mice were then exposed to 5 Gy sin-
gle dose irradiation at 20 days after cell inoculum.
No differences were appreciable in the tumor take rate
of miR-205 and control xenografts (which was 100% in
all experimental groups), although the growth of
non-irradiated xenograft tumors originated from
miR-205-reconstituted DU145 cells was delayed com-
pared to those arising from control cells (Fig. 3b and c).
Since a comparable proliferation rate (in terms of plating
efficiency in the clonogenic assay) was observed in vitro
for both cell lines, such a growth delay was likely due to
limited local invasive capabilities of miR-205 expressing
cells, consistent with our previous finding indicating the
ability of the miRNA to counteract EMT and impair mi-
gration and invasive properties in DU145 cells following
transfection with a miR-205 synthetic precursor [17].
Interestingly, miR-205 enhanced the effect of radiation
also in vivo, as indicated by a statistically significant re-
duction in tumour growth upon irradiation compared to
controls (Fig. 3b) and, especially, by the significantly in-
creased time for DU145 xenografts to reach 1000mm3
tumour burden with respect to controls (Fig. 3c).
Repression of the PKCε-EGFR-DNA-PK axis as main
determinant of miR-205-mediated radiosensitization
To dissect the molecular determinants underlying
miR-205-induced radiosensitizing effect in PCa cells, we
explored the possible role of miRNA target genes rele-
vant to radiation response. Target choice was based on
previous findings indicating that PKCε plays a central
role in radiation response of A549 lung carcinoma cells
by inducing nuclear translocation of EGFR and activa-
tion of DNA-PK [23], together with the evidence that
miR-205 increased radiation response of breast cancer
models through ZEB1 suppression and consequent in-
hibition of homologous recombination (HR) repair of
DNA-DSBs [4].
Phenocopy experiments were carried out to assess the
radiation response of DU145 cells upon knockdown of
PKCε or ZEB1 with specific siRNAs able to reduce both
mRNA and protein at levels comparable to those
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observed following miR-205 reconstitution (Fig. 4a and
b, left panels). Down-regulation of either gene was able
to induce a radiosensitizing effect comparable (or
slightly greater, although not significantly different) to
that observed following miR-205 reconstitution, as indi-
cated by the clonogenic cell survival curves following ex-




Fig. 1 miR-205 enhances PCa cell sensitivity to radiation. (a) (Left panel) qRT-PCR showing miR-205 expression kinetics normalized to RNU-48 in
DU145 and PC-3 cells up to 240 h upon miR-205 reconstitution, compared to control cells. Data are reported as relative quantity (RQ) ± SD with
respect to Neg cells. All RQ values are statistically significant considering p < 0.0001. (Right panel) Clonogenic cell survival of DU145 and PC-3 cells
transiently transfected with miR-205 or Neg and exposed to increasing doses of irradiation (2, 4, 6 and 8 Gy). The surviving fraction is reported as mean
± SD values from 3 independent experiments. (b) (Left panel) qRT-PCR showing miR-205 amount normalized to RNU-48 in Vec miR-205-transfected
DU145 cells, compared to control cells. Data are reported as relative quantity (RQ) ± SD with respect to Neg cells. (Right panel) Clonogenic cell survival
of DU145 cells stably transfected with miR-205 or Neg vector and exposed to irradiation (2, 4, 6 and 8 Gy). The surviving fraction is reported as mean ±
SD values from 3 independent experiments. The level of significance was represented as *p < 0.05, **p < 0.01, ***p < 0.001, Student’s t-test
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While miR-205-induced inhibition of ZEB1 and of the
ubiquitin-conjugating enzyme Ubc13, and the conse-
quent decrease in the ability to repair DNA damage by
the homologous recombination (HR) pathway, has been
exhaustively documented as a main responsible for the
miRNA radiosensitizing effect in breast cancer cells [4],
the role of PKCε in miR-205-mediated increased radi-
ation response of tumour cells has never been
investigated.
Our finding that PKCε knockdown affects PCa cell ra-
diosensitivity similarly to miR-205 restoration does not
per se demonstrate that miRNA-induced radiosensitiza-
tion directly relies on PKCε down-regulation. To address
this point, a target protection approach was pursued.
Specifically, DU145 and PC-3 cells were co-transfected
with miR-205 mimic and a miR-Mask, a custom oligo-
nucleotide designed to be fully complementary to
miR-205 binding site within PKCε 3’UTR, to assess
whether the disruption of miRNA-target interaction
could abolish miR-205 radiosensitizing effect. Notably,
the miR-Mask was able to almost completely restore
PKCε transcript and protein expression levels, thus
A B
C
Fig. 2 miR-205 impairs cell repair of radiation-induced DNA damage. (a) Representative immunofluorescence images of nuclear γH2AX foci (cell
nuclei: blue; γH2AX foci: green) in DU145 cells at 1, 4 and 8 h after exposure to 4 Gy of irradiation. (b) Kinetics of γH2AX foci resolution in Neg- or
miR-205-reconstituted DU145 cells, expressed as mean number of cells containing > 10 γH2AX foci at 1, 4 and 8 h after exposure to 4 Gy of
irradiation (IR). Data are reported as mean ± SD values from 3 independent experiments. (c) (Left panel) Photomicrographs showing formation of
Comets in Neg- or miR-205-transfected DU145 cells at 4 h after exposure to 4 Gy of irradiation. (Right panel) Quantification of tail moments
counted in at least 200 cells per group, reported as mean ± SD values from 3 independent experiments. The level of significance was represented
as ***p < 0.001, Student’s t-test
A B C
Fig. 3 miR-205 enhances PCa xenograft response to radiation therapy. DU145 cells stably transfected with miR-205 or Neg vector (1 × 107) were
implanted subcutaneously into the right flank of SCID mice. When tumors reached ~ 100mm3, mice were randomly assigned to four groups (8
mice/group) and treated with 5 Gy single dose irradiation locally delivered to the tumor. (a) qRT-PCR showing miR-205 amount normalized to
RNU-48 in Vec miR-205-tumours, compared to control ones. (b) Tumor growth volume (mm3) measured with a Vernier caliper on indicated days
after cell injection. (c) Kaplan-Meier plot of mouse tumor growth to 1000mm3
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confirming PKCε as a direct target of miR-205 (Fig. 5a).
Interestingly, the presence of miR-Mask abrogated, al-
though partially, miR-205 radiosensitizing effect in both
PCa cell lines, substantiating a scenario proposing PKCε
down-regulation as an important determinant of
miR-205-induced enhancement of radiation response
(Fig. 5b).
PKCε has been reported to be up-regulated upon radi-
ation exposure in A549 lung carcinoma cells [25] and to
stimulate radiation-induced damage repair through
EGFR phosphorylation and nuclear accumulation, which
in turn phosphorylates and activates DNA-PK thus trig-
gering non-homologous end joining (NHEJ) pathway
[23]. Consistently, we found that at 30 and 60min
following exposure to 4 Gy irradiation, DU145 control
cells displayed enhanced levels of PKCε, pEGFR (T654)
and nuclear pDNA-PK (T2609), which were not appre-
ciable in miR-205-reconstituted cells (Fig. 5c).
We have previously reported that miR-205 replacement
in PCa cells induces an enhancement of cisplatin cytotoxic
activity, as a consequence of autophagy impairment medi-
ated by the downregulation of the lysosome-associated
proteins LAMP3 and RAB27A [22]. Here, we found that
the silencing of LAMP3, but not RAB27A, significantly
enhanced the radiation response of DU145 cells, as indi-
cated by the reduction of survival fractions at 2 Gy




Fig. 4 PKCε and ZEB1 down-regulation phenocopies miR-205-induced radiosensitization. (a) (Left panel) qRT-PCR showing PKCε mRNA amount in
miR-205- or siPKCε-transfected DU145 cells, compared to control cells, normalized to GAPDH. Data are reported as relative quantity (RQ) ± SD with
respect to Neg cells. (Middle panel) Western blot analysis showing PKCε protein amount in DU145 cells upon transfection with Neg, miR-205 or
siPKCε. β-Actin was used as equal protein loading controls. Cropped images of selected proteins are shown. (Right panel) Clonogenic cell survival
of DU145 cells transfected with miR-205 or siPKCε. The surviving fractions following the indicated doses of irradiation are reported as mean ± SD
values from 3 independent experiments. (b) (Left panel) qRT-PCR showing ZEB1 mRNA amount in miR-205- or siZEB-transfected DU145 cells,
compared to control cells, normalized to GAPDH. Data are reported as relative quantity (RQ) ± SD with respect to Neg cells. (Middle panel)
Western blot analysis, and corresponding relative quantification, showing ZEB1 protein amount in DU145 cells upon transfection with Neg, miR-
205 or siZEB1. β-Actin was used as equal protein loading controls. Cropped images of selected proteins are shown. (Right panel) Clonogenic cell
survival of DU145 cells transfected with miR-205 or siZEB1. The surviving fractions are reported as mean ± SD values from 3 independent
experiments. The level of significance was represented as *p < 0.05, **p < 0.01, ***p < 0.001, Student’s t-test
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Overall, our findings suggest that miR-205 exerts its
radiosensitizing effect mainly by impairing DNA repair
pathways through the inhibition of ZEB1 and the suppres-
sion of PKCε-EGFR-DNA-PK axis, respectively, ultimately
resulting in a decrease removal of radiation-induced DNA
lesions and consequent enhancement of PCa cell suscepti-
bility to radiation. Moreover, miR-205-induced impair-
ment of the autophagy flux, mainly through LAMP3
downregulation, could represent an additional mechanism
by which the miRNA exerts its radiosensitizing effect.
Discussion
Results obtained in experimental models have demon-
strated a direct involvement of selected miRNAs in con-
trolling tumor radiation response, thus revealing an
entirely new mechanism of radioresistance but also en-
visaging a possible novel approach of radiosensitization
based on the modulation of specific miRNAs [26].
In this study, we showed that reconstitution of miR-205,
the expression of which is down-regulated in primary and,
even more, in metastatic PCa lesions [17–19], was able to
enhance radiation response in both in vitro and in vivo
PCa models. miR-205 is known to exert oncosuppressive
functions in PCa [17, 20–22], some of which are relevant
to radiation-response. Specifically, miR-205 was found to
counteract EMT in PCa cells through the suppression of
PKCε [17]. EMT was reported to be related to radioresis-
tance in many cancers [5–8]. In this context, we and
others already showed the relevance of some EMT-related
miRNAs, including miR-200c [27], miR-203 [28], miR-204
[29] and miR-875-5p [16] in determining the radiation re-
sponse of experimental tumor models.
Since it is well known that radiosensitivity depends in
part on tumor cell kinetics, being G2-M the most radio-
sensitive phase of the cell cycle [30], the recently estab-
lished role for PKCε in the control of mitotic spindle
organization in transformed cell models [31] could also
contribute to the miR-205-mediated radiosensitizing ef-
fect. Most importantly, PKCε also plays a role in the nu-
clear translocation of EGFR, a main mechanism of
A B C
Fig. 5 Repression of the PKCε-EGFR-DNA-PK axis as main determinant of miR-205-mediated radiosensitization. (a) (Left panel) qRT-PCR showing
PKCε mRNA amount in DU145 or PC-3 cells transfected withmiR-205, in the presence or absence of miR-Mask, compared to control cells, normalized to
GAPDH. Data are reported as relative quantity (RQ) ± SD with respect to Neg cells. (Right panel) Western blot analysis showing PKCε protein amount in DU145
and PC-3 cells uponmiR-205-reconstitution in the presence or absence of miR-Mask. β-Actin was used as equal protein loading controls. Cropped images of
selected proteins are shown. (b) Clonogenic cell survival of DU145 (upper panel) or PC-3 (lower panel) cells transfected with miR-205, miR-Mask or both. The
surviving fractions are reported as mean± SD values from 3 independent experiments. (c) Forty-eight h after transfection with Neg or siPKCε, DU145 cells
were exposed to 4 Gy and 30 and 60min later harvested for total protein collection or subcellular protein fractionation and western blot analysis. Results
showing the total amount of PKCε and phospho-EGFR (upper panel) and of nuclear phospho-DNA-PK levels (lower panel) are reported. Vinculin and HDAC
were used as control for total and nuclear fractions, respectively. Cropped images of selected proteins are shown. The level of significance was represented as
*p< 0.05, **p< 0.01, ***p< 0.001, Student’s t-test
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tumor radioresistance [23]. Specifically, it has been
shown that radiation-induced nuclear EGFR presented
PKCε-mediated increased phosphorylation at T654 [23].
EGFR contributes to radiation resistance, at least in part,
by interacting with the catalytic subunit of DNA-PK and
increasing the enzyme activity through stabilization of
the phosphorylated forms of the protein at specific
serine (S2056) and threonine (T2609) residues, which
are essential for DNA double-strand break repair by
NHEJ pathway [32]. Indeed, we found that
siRNA-mediated PKCε down-regulation was able to
phenocopy the radiosensitizing effect induced by
miR-205 and to reduce the accumulation of phos-
phoEGFR and phosphoDNA-PK. Consistently, the inhib-
ition of miR-205-PKCε interaction through the use of a
miRNA mask almost completely abolished the radiosen-
sitizing effect of the miRNA as a consequence of the
complete recovery of PKCε expression.
miR-205 reconstitution in experimental models of human
breast cancer, another tumor type characterized by a re-
duced expression of the miRNA [33], was found to improve
the radiation response by directly targeting ZEB1 and the
ubiquitin-conjugating enzyme Ubc13, thus inhibiting
HR-mediated repair of DNA-DSBs [4]. Consistently, in this
study we found a significant inhibition of ZEB1 expression,
at both mRNA and protein level, following miR-205 recon-
stitution in PCa cell lines. In addition, siRNA-mediated
ZEB1 silencing was able to recapitulate miR-205 radiosensi-
tizing effect, thus confirming a functional role of ZEB1 in
determining the radiation response also in PCa cells.
A B
Fig. 6 LAMP3 downregulation recapitulates miR-205 induced radiosensitizing effect. (a) Surviving fractions at 2 Gy of DU145 cells transfected with
either miR-205, siPKCε, siZEB1, siLAMP3 or siRAB27A are reported as mean ± SD values from 3 independent experiments. The level of significance
was represented as **p < 0.01, ***p < 0.001, Student’s t-test. (b) Western blot analysis, and corresponding relative quantification, showing LAMP3
(upper panel) and RAB27 (lower panel) protein amount in DU145 cells upon transfection with siLAMP3 or siZEB1, respectively. Vinculin was used as
equal protein loading controls. Cropped images of selected proteins are shown
miR-205
SENSITIVITY TO RADIATION
Fig. 7 The working model of miR-205 radiosensitizing effect. MiR-
205-induced suppression of ZEB1 and PKCε leads to the impairment
of DNA-repair, thus resulting in an enhancement of cell sensitivity
to radiation
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The emerging role of miR-205 as a negative regulator of
both NHEJ and HR repair pathways (Fig. 7) is supported
by the significantly reduced clearance of radiation-induced
DNA-DSBs we observed in miRNA-reconstituted PCa
cells, in terms of increased residual γH2AX foci and ex-
tended comet tail moments at different interval following
irradiation.
In addition, consistent with the previously reported
ability of miR-205 to enhance the response of PCa to
cisplatin treatment through autophagy impairment [22],
results of this study suggest a possible role of LAMP3
downregulation in the miRNA-mediated enhancement
of PCa cell radiation response.
Although data collected in PCa and breast cancer
models support the clinical interest in developing a
novel miR-205-based radiosensitization approach, the
evidence that involvement of specific miRNAs in the
onset of radiation resistance seems to be cell/tissue
specific represents a constraint for the clinical exploit-
ation of miRNA-based therapeutic molecules. In this
context, it was found that Sp1-mediated transcrip-
tional activation of miR-205 promotes radioresistance
in esophageal squamous cell carcinoma [34], where
the miRNA was reported to exert oncogenic functions
[35], and that miR-205 determines the radioresistance
of human nasopharyngeal carcinoma by directly tar-
geting PTEN [36], thus envisaging a possible opposite
role of the miRNA in controlling radiation response
as a function of tumour cell type, based on the avail-
ability of specific targets.
Conclusions
In conclusion, this is the first report indicating that
miR-205 reconstitution enhances radiation response in
prostate cancer cell and xenograft models. We also pro-
posed that such an effect may mainly rely on DNA repair
impairment as a consequence of PKCε and ZEB1 targeting,
as suggested by the evidence that RNAi-mediated silencing
of either gene was able to phenocopy miR-205 radiosensi-
tizing effect. Cumulatively, our results support the clinical
interest in developing a novel therapeutic approach based
on miR-205 reconstitution to increase prostate cancer re-
sponse to radiotherapy.
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